A study to evaluate the effectiveness and safety of eloralintide in adults with obesity or overweight without type 2 diabetes.

3 1

What is this study about?

This study aims to evaluate the effectiveness and safety of a medication called Eloralintide, which is also known by the code LY3841136. The research focuses on individuals living with Obesity, a condition where excess body fat may affect health, or those who are Overweight but do not have Type 2 Diabetes, a chronic condition that affects how the body processes blood sugar.

Participants in the study will receive either the study drug or a placebo through a subcutaneous injection, which means the medicine is delivered by a needle into the fatty layer of tissue just under the skin. The medication is provided as a solution for injection in a pre-filled syringe and is intended to be used once every week. This research is designed to determine if Eloralintide can lead to a greater reduction in body weight compared to the placebo over a period of time.

Who Can Join the Study?

Be a person who is overweight (weighing more than what is considered healthy for your height) or has obesity (a medical condition where excess body fat has accumulated to an extent that it may affect health).
If you are overweight, you must also have at least one of the following conditions: high blood pressure (when the force of blood against your artery walls is too high), high cholesterol (having too many fatty substances in your blood), obstructive sleep apnea (a condition where your breathing repeatedly stops and starts while you sleep), or heart disease (a general term for various conditions that affect the heart).
Have maintained a stable body weight, meaning your weight has not changed by more than 5% in the 90 days before starting the study.
Have previously reported at least one attempt to lose weight through dietary efforts (changing what you eat) that was not successful.
Be either male or female.

Who Cannot Join the Study?

You cannot participate if you have type 1 diabetes or type 2 diabetes, which are conditions where your body has trouble managing blood sugar (the amount of sugar in your blood).
You are not eligible if you have recently had or are planning to have surgery, an endoscopic procedure (a medical test where a tube with a camera is used to look inside your body), or any device-based therapy (using a medical tool or implant) to help you lose weight.
You cannot join if you have experienced a serious heart condition, such as a heart attack or irregular heartbeat, in the 90 days before your first check-up for this study.
You are excluded if you have used any medications (prescription or over-the-counter drugs) or alternative remedies (such as herbal supplements) intended to help with weight loss in the 90 days before your first check-up.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.	Lodz	Poland
Diabetologische Schwerpunktpraxis Dr. Staudenmeyer & Dr. Schiwietz	Lingen (Ems)	Germany
Diabeteszentrum Hamburg West	Hamburg	Germany
Kormont	Kluisbergen	Belgium
Diabetes-Zentrum-Wilhelmsburg GbR	Hamburg	Germany
Legeartis Poradnie Specjalistyczne Sp. z o.o.	Bialystok	Poland
Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik	Bialystok	Poland

Other Sites

Site Name	City	Country
Ambenet GmbH Das Ambulante Behandlungsnetz	Leipzig	Germany
Medizentrum Essen Borbeck	Essen	Germany
Terpa Sp. z o.o. sp.k.	Lublin	Poland
InnoDiab Forschung GmbH	Essen	Germany
R.E.D. Institut fuer medizinische Studien und Fortbildung GmbH	Oldenburg In Holstein	Germany
Medyczne Centrum Diabetologiczno-Endokrynologiczno-Metaboliczne Diab-Endo-Met Sp. z o.o.	Cracow	Poland
Jessa Ziekenhuis	Hasselt	Belgium
Anima	Alken	Belgium
CRS Clinical Research Services Management GmbH	Berlin	Germany
CENTRUM ZDROWIA METABOLICZNEGO PAWEL BOGDANSKI	Poznan	Poland
Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden	Dresden	Germany
Praxis Sauter & Vorbach	Wangen im Allgäu	Germany
BAG Drs. Med. Quist PartG	Mainz	Germany
Evvwaz Ssy z oawa	Lublin	Poland
Sinnhexwqrq Pwkfajhci Sgcrniq Kixocfico Ng 1 Ibbwvsgbgqsamrgwau Sbtrsbq Svyljsivr Udrjypizylis Mzdmcfeidy W Khkswnutku	Zabrze	Poland
Muh Hjaafbbblm Gbrjmbvwaer Geyj	Duisburg	Germany
Piyfsygjd Bzhbj Keugysakpyu Seqae	Wroclaw	Poland
Zgyntho fik kyzpqtuxa Fweojuauo	Cologne	Germany

Trial status

Country	Status	Recruitment Start
Belgium	Recruiting	15.04.2026
Germany	Recruiting	15.04.2026
Poland	Recruiting	15.04.2026

Trial locations

Investigated drugs:

LY3841136 SODIUM

Eloralintide is an experimental medication being tested to see if it helps adults who are overweight or have obesity lose weight. It is given as an injection under the skin once a week.

Obesity – This condition involves an excessive accumulation of body fat that may impair health. It often occurs when there is an imbalance between the energy consumed through food and the energy used by the body. Over time, the amount of stored fat continues to increase. This process is driven by various factors including diet and physical activity levels.

Overweight – This condition refers to having a body weight that is higher than what is considered healthy for a given height. It serves as a state where the body carries more weight than is typical for an individual’s frame. The condition can progress if the surplus of calories continues over a long period. It is often measured by comparing weight to height.

Trial ID:

2025-523657-34-00

Protocol code:

J3R-MC-YDAG

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

A study to evaluate the effectiveness and safety of eloralintide in adults with obesity or overweight without type 2 diabetes.

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?